Have a feature idea you'd love to see implemented?
Let us know!
QNCX Quince Therapeutics Inc
Price (delayed)
$0.7
Market cap
$30.29M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.26
Enterprise value
$36.69M
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence
Highlights
The quick ratio has plunged by 87% YoY and by 16% from the previous quarter
The net income has shrunk by 75% QoQ and by 74% YoY
Key stats
What are the main financial stats of QNCX
Market
Valuations
Earnings
Shares outstanding
43.28M
Market cap
$30.29M
Enterprise value
$36.69M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.64
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$53.01M
EBITDA
-$52.62M
Free cash flow
-$28.09M
Per share
Balance sheet
Liquidity
EPS
-$1.26
Free cash flow per share
-$0.65
Book value per share
$1.09
Revenue per share
$0
TBVPS
$1.69
Total assets
$134.83M
Total liabilities
$87.86M
Debt
$14.29M
Equity
$46.97M
Working capital
$53.12M
Debt to equity
0.3
Current ratio
6.15
Quick ratio
5.76
Net debt/EBITDA
-0.12
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-38.8%
Return on equity
-73.4%
Return on invested capital
-80.7%
Return on capital employed
-42.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
QNCX stock price
How has the Quince Therapeutics stock price performed over time
Intraday
0%
1 week
-9.68%
1 month
0%
1 year
-35.78%
YTD
-33.33%
QTD
-9.82%
Financial performance
How have Quince Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$49.08M
Net income
-$53.12M
Gross margin
N/A
Net margin
N/A
The net income has shrunk by 75% QoQ and by 74% YoY
QNCX's operating income has dropped by 71% since the previous quarter and by 51% year-on-year
Growth
What is Quince Therapeutics's growth rate over time
Valuation
What is Quince Therapeutics stock price valuation
P/E
N/A
P/B
0.64
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 66% since the previous quarter and by 52% year-on-year
QNCX's P/B is 86% below its 5-year quarterly average of 4.6 but 7% above its last 4 quarters average of 0.6
The equity has decreased by 46% YoY and by 37% QoQ
Efficiency
How efficient is Quince Therapeutics business performance
The ROE has shrunk by 129% YoY and by 99% QoQ
The ROIC has dropped by 72% since the previous quarter and by 47% year-on-year
Quince Therapeutics's ROA has plunged by 60% from the previous quarter and by 26% YoY
Dividends
What is QNCX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for QNCX.
Financial health
How did Quince Therapeutics financials performed over time
QNCX's total assets is 53% greater than its total liabilities
The quick ratio has plunged by 87% YoY and by 16% from the previous quarter
The current ratio has plunged by 86% YoY and by 14% from the previous quarter
The debt is 70% lower than the equity
QNCX's debt to equity has surged by 58% since the previous quarter
The equity has decreased by 46% YoY and by 37% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.